Dr. Bayarsaikhan is presenting Cerviray A.I.
[View original text]
On 14th of October, AIDOT announced that it introduced its artificial intelligence (AI)-based cervical cancer screening system "Cerviray A.I." at the "Health Technology 2022", the
international exhibition held in Ulaanbaatar, Mongolia, for three days from the 7th to the 9th of October.
A total of 80 institutions, including 13 public and private hospitals, 14 medical device and device organizations, 41 pharmaceutical factories and drug supply organizations, participated in Health Technology 2022, with 10,000 visitors and 4,500 of them receiving specialist treatment.
Mongolia is a highland country with an average altitude of about 1600m, 40% of which is mountainous. There are not many medical facilities and the market is small, but it is one of
the places with high demand for medical services. In addition, cervical cancer is the number one disease that occurs in Mongolian women, and the demand for screening is very high.
Cerviray is a system that combines a portable device with software that displays the presence, severity, and disease status of a disease. It is expected that Mongolian women will be
able to improve their quality of life by receiving cervical cancer screening.
AIDOT is currently conducting a pilot project for 300 patients, led by Dr. Bayarsaikhan Luvsandorj from the National Cancer Center in Gobi, Mongolia, and plans to expand nationwide
next year to start full-fledged cervical cancer tests.
Hong-Suk Lee, the manager of AIDOT's global sales and marketing headquarters said, "The contract with a local medical device company in Mongolia has already been completed and we have secured more than $30,000 in initial exports. We will spare no effort to fight cervical cancer in Mongolia by 2023."
14th.Oct.2022 / Rapportian / Reporter Hee-seok Jeong
Comments can be added by Member only